Kristine Ball

Kristine M. Ball joined Soteria in 2020 as Chief Executive Officer and brings over 25 years of experience in the life-sciences industry. Most recently, Ms. Ball served as Senior Vice President of corporate strategy and Chief Financial Officer of Menlo Therapeutics, Inc. from 2017 through Menlo’s merger with Foamix, Inc. in March 2020. At Menlo, Ms. Ball was responsible for leading all administrative functions including strategic planning, corporate development, commercial, human resources, legal, finance, and IT. She led Menlo’s initial public offering and the cross-functional team responsible for the merger with Foamix.

Prior to joining Menlo, Ms. Ball served as Senior Vice President and Chief Financial Officer of Relypsa, Inc. from 2012 through the company’s acquisition in 2016 by Vifor Pharma for $1.5 billion. At Relypsa, Ms. Ball led the company’s initial public offering and the cross-functional team responsible for the merger with Vifor and was a member of the senior team responsible for the launch and commercialization of its lead candidate, patiromer (US brand name Veltassa). Prior to Relypsa, Ms. Ball served as SVP, Finance and Administration and CFO of KAI Pharmaceuticals, Inc. (acquired by Amgen) and Vice President, Finance at Exelixis, Inc.

Ms. Ball serves as a member of the board of directors of Atreca, Inc. and also served on the board of directors of Forty Seven Inc. prior to the company’s acquisition by Gilead in 2020. Ms. Ball holds a B.S. from Babson College.